중간엽줄기세포/약용 시그널 세포(MSC) 시장 : 진보와 응용(2025년)

Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2025

US $ 4,197 ￦ 5,835,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,797 ￦ 6,669,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,297 ￦ 7,364,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

MSC는 다능성 세포로, 그 다용도성과 다양한 용도를 반영하여 간엽줄기세포, 약용신호세포, 간엽간질세포 등으로 불리며, 골아세포, 연골세포, 근육세포, 지방세포 등 다양한 세포형으로 분화할 수 있습니다. 조직 회복을 촉진하는 인자를 분비하고, 항염증 작용과 항섬유화 작용을 통해 미세환경을 조절하는 독특한 능력을 가지고 있으며, 재생의료에 있으며, 필수적인 존재가 되고 있습니다. 또한 MSC는 면역침습성 특성으로 인해 동종 이식에 특히 적합합니다.

MSC는 재생의료, 화장품, 배양육 생산 등 다양한 산업에서 중요한 원료로 활용되고 있습니다.

전 세계에서 12개의 MSC 기반 치료제가 다양한 적응증으로 승인되었으며, 대부분 한국, 일본, EU에 집중되어 있습니다.

특히 한국에서는 5개 제품이 승인되고 있습니다. 구체적으로 한국에서는 Anterogen의 Queencell, Pharmicell의 Cellgram AMI, Anterogen의 Cupistem, Medipost의 Cartistem, Corestem의 NeuroNataR 등 5개 제품이 승인되고 있습니다. 일본에서는 JCR의 Temcell HS와 Nipro Corporation의 Stemirac 등 2개 제품이 승인되고 있습니다. 인도에서는 1개 제품이 승인되었습니다. 이러한 진전에도 불구하고 미국 FDA의 승인을 받은 MSC 기반 치료제는 아직 없습니다.

화장품 시장도 MSC 유래 제품, 특히 엑소좀을 빠르게 채택하여 노화 방지 및 재생 특성을 활용하고 있으며, L'Oreal 및 Johnson & Johnson과 같은 회사는 이 분야에 많은 투자를 하고 있습니다. 마찬가지로 배양육 기업은 MSC를 근육과 지방 세포 생산에 활용하여 맛과 질감을 개선하기 위해 MSC를 활용하고 있으며, 업사이드 푸드(Upside Foods)와 굿미트(Good Meat)의 랩그로운 치킨과 같은 획기적인 승인은 이 산업이 더욱 성장할 수 있는 길을 열었습니다.

MSC를 기반으로 한 유전자 편집이 확대되고 있으며, 항종양 유전자 및 치료 인자의 과발현을 가능하게 하고 있습니다. 연구자들은 또한 3D 프린팅과 인공장기 제조에 MSC를 활용하는 방안을 모색하고 있으며, 향후 10년 내에 비약적인 발전이 예상됩니다.

중간엽줄기세포/약용 시그널 세포(MSC) 시장에 대해 조사했으며, MSC 임상시험, 과학논문, 특허, 자금조달 이벤트, 공동 연구의 비율을 소개하고 있습니다. MSC 기반 치료제 파이프라인을 소개하고, 시장 기회와 위협을 식별하고, 향후 방향성과 새로운 용도를 모색합니다. 또한 125개의 주요 경쟁사가 제공하는 혁신적인 MSC 제품, 서비스, 기술을 소개하고 있습니다. 마지막으로 세계 MSC 시장의 상세한 시장 규모를 지역별, 사업 분야별로 분류하고, 2031년까지의 예측을 게재하고 있습니다.

목차

제1장 보고서 개요

제2장 중간엽줄기세포(MSC) : 개요

• 기술로서 hMSC의 안정화
• MSC가 재생의료에 미치는 영향
• MSC 명명법의 타임라인
• MSC의 공급원
• MSC의 세포 표면 마커
• MSC의 in vitro 분화능
• MSC로부터 분비되는 가용성 요인
• MSC에 존재하는 줄기세포 유전자
• MSC의 유형과 생물의학적 응용
• MSC의 특성에 중요한 유전자

제3장 MSC 기반 임상시험의 상황

제4장 중간엽줄기세포(MSCS) : 특허 상황

제5장 MSCS에 관한 출판된 과학논문

제6장 MSC 제조 플랫폼 : 개요

• MSC 분리 방법
• 세포 증식 : 기존 배양으로부터 바이오리액터로
• MSC의 다운스트림 처리
• 자기 및 동종 MSC 제조의 비교
• MSC 소규모 제조의 경제성
• MSC의 대규모 제조

제7장 세포·유전자 치료 수탁제조

제8장 MSC의 기능을 높이는 바이오엔지니어링 솔루션

• MSC의 소분자 프라임
• MSC의 입자 공학
• MSC의 유전자 공학
• 항암 치료제를 생산하기 위한 바이오엔지니어링 MSC의 예
• 신경질환을 위한 인공 MSC
• 심혈관질환을 위한 인공 MSC
• 폐손상을 위한 인공 MSC
• 당뇨병을 위한 인공 MSC
• MSC 관리를 개선하기 위한 바이오엔지니어링 어프로치

제9장 MSCS가 대처하는 주요 질환

제10장 MSC 부문에서의 최근 협업, 2020-2024년

제11장 시장의 MSC 기반 제품

• 승인된 MSC 요법
• 시판 바이오소재 캐리어 기반 MSC 및 MSC 전구세포
• MSC/MSC 유래 엑소좀을 포함한 외용 화장품

제12장 시장 분석

• MSC 요법의 시장 규모
• 중간엽줄기세포(MSC)의 세계 수요

제13장 기업 개요

• Advancells
• Aegle Therapeutics
• AGC Biologics
• AlloSource, Inc.
• Ambulero
• American CryoStem Corporation
• American Type Culture Collection(ATCC)
• Amniotics
• Andelyn Biosciences
• Anemocyte S.r.l
• Anterogen, Co., Ltd.
• Avid Bioservices, Inc.
• Bacthera
• Baylx, Inc.
• BioCardia
• BioCentriq
• BioEden, Inc.
• Bioinova s.r.o
• BioRestorative Therapies
• Bioscience Institute S.p.A
• Blue Horizon International, LLC
• Boehringer Ingelheim BioXellence
• Bonus Biogroup, Ltd.
• BrainStorm Cell Therapeutics, Inc.
• Catalent
• CCRM
• Cell2Cure ApS
• Cell Care Therapeutics
• Cellcolabs
• CELLeBRAIN
• Cellipont Bioservices
• Celprogen, Inc.
• CellProthera
• CellResearch Corporation, Pte, Ltd.
• Cell Surgical Network(CSN)
• Celltex Therapeutics Corporation
• CellTherapies
• Cellular Biomedicine Group
• Charless River Laboratories
• CHIESI Farmaceutici S.p.A
• Citius Pharmaceuticals, Inc.
• CorestemChemon, Inc.
• Creative Bioarray
• Creative Medical Technology Holdings, Inc.
• Curia Global, Inc
• Cynata Therapeutics, Ltd.
• Cytovance Biologics
• Defined Bioscience, Inc.
• Direct Biologics
• eQcell, Inc.
• Excellos
• Exosla Therapeutics
• EXOSOMEplus
• Exothera
• Fujifilm Diosynth Biotechnologies
• Future Cell Japan, Co., Ltd.
• Genezen
• GenScript Biotech Corporation
• Hope Biosciences, LLC
• Implant Therapeutics, Inc.
• INCELL Corporation LLC
• InGeneron GmbH
• Invitrx Therapeutics
• Japan Tissue Engineering, Co., Ltd.(J-TEC)
• JCR Pharmaceuticals, Co., Ltd.
• Jointechlabs
• Kangstem Biotech, Co., Ltd.
• Kimera Labs
• LifeCell
• Longeveron
• Lonza Group, Ltd
• Lorem Cytori USA, Inc.
• MEDPOST
• Mesoblast, Ltd.
• Millipore Sigma
• NecstGen
• NextCell
• NIPRO Corporation
• Novadip Biosciences
• Novus Biologicals, LLC
• NuVasive
• OCT Therapies & Research Pvt., Ltd
• OmniaBio, Inc.
• Orthocell, Ltd.
• Ossium Health
• Personal Cell Sciences Corporation
• Personalized Stem Cells, Inc.
• Pfizer CentreOne
• Pluri Biotech, Ltd.
• Porton Advanced
• Prometheus Life Technologies
• PromoCell GmbH
• PuREC, Co., Ltd.
• Regrow Biosciences
• Reliance Life Sciences, Pvt., Ltd.
• Remedy Cell, Ltd.
• Rentschler Biopharma
• REPROCELL USA, Inc.
• Resilence
• RESTEM, LLC
• RHEACELL GmbH & Co., KG
• Richter-HELM
• RoosterBio, Inc.
• RTI Surgical
• Samsung Biologics
• San Bio, Co., Ltd.
• Smith & Nephew, Inc.
• StemBioSys, Inc.
• STEMCELL Technologies, Inc.
• Stemedica Cell Technologies, Inc.
• Stemmatters
• StemMedical
• Stempeutics Research Pvt., Ltd.
• StromaBio AB
• TaiwanBio Therapeutics, Co., Ltd.
• Takeda Pharmaceutical, Co., Ltd.
• ThermoFisher Scientific
• Vericel Corporation
• Wuxi App Tec
• Xintela AB

도표 색인

표 색인

KSA

영문 목차

영문목차

EXECUTIVE SUMMARY

MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, their immuno-evasive properties make MSCs particularly suitable for allogenic transplantation.

MSCs serve as vital raw materials across numerous industries, including regenerative medicine, cosmeceuticals, and cultured meat production.

Key applications include:

• Cell-based therapies for musculoskeletal diseases, spinal injuries, and cardiovascular conditions.
• Engineered tissues and organs, such as skin, bone, blood vessels, and liver.
• Cell-derived products, such as exosomes and growth factors, utilized in cosmetics and skincare.
• Cultured meat production, leveraging MSCs' role in muscle development and their ability to differentiate into muscle and fat cells.

Globally, 12 MSC-based therapies have been approved for various indications, with the majority concentrated in South Korea, Japan, and the EU.

Specifically, the Republic of Korea has approved five products: Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem. Japan has approved two products: Temcell HS from JCR Pharmaceuticals and Stemirac from Nipro Corporation. The EMA in Europe has approved two products: Holoclar from Chiesi Farmaceutici and Alofisel from TiGenix/Takeda. India has approved one product: Stempeucel from Stempeutics. Iran has approved one product: MesestroCell developed by Cell Tech Pharmed. Finally, Australia has approved one product: Remestemcel-L from Mesoblast.

Despite this progress, no MSC-based therapeutic have yet received U.S. FDA approval, although the FDA is actively reviewing Mesoblast's Remestemcel-L.

The cosmeceutical market is also rapidly adopting MSC-derived products, particularly exosomes, to leverage their anti-aging and regenerative properties, with companies like L'Oreal and Johnson & Johnson investing heavily in this space. Similarly, cultured meat companies are utilizing MSCs for producing muscle and fat cells, enhancing taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further growth in this industry.

MSC-based gene editing is expanding, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are also exploring the use of MSCs in 3D printing and engineered organ production, with breakthroughs anticipated in the next decade.

Importantly, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, enabling large-scale therapeutic development. Today there are at least eight companies who are involved with the development of iPSC-derived MSCs therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics.

There are also over 1,670 clinical trials involving MSCs are registered on ClinicalTrials.gov. Nearly 75% (three-quarters) of these clinical studies are using MSCs for the development of regenerative medicine (RM) products. Approximately 14% of the studies are using MSCs for disease modeling. The remaining 11% of the studies are using MSCs for drug discovery and cytotoxicity testing applications.

Challenges in these trials include maintaining MSC phenotype and functionality during expansion. However, ongoing advancements suggest a promising future, with projections for at least 50 globally approved MSC-based products by 2040, averaging 3-4 new approvals annually.

Key Players in MSC Research Products

The demand for MSC-based research products has surged in recent years, with major suppliers expanding their portfolios. Companies like RoosterBio have increased the access to quality MSCs through supply chain industrialization, standardized cell bank product forms, and fit-for-purpose cGMP-compatible cells and media systems.

Other leading MSC research product suppliers include: PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC.

Challenges and Opportunities

While MSC commercialization faces hurdles-such as scalability and regulatory approval-opportunities abound. The market for MSC-based products is poised for notable growth across the research, therapeutic, cosmetic, and food industries.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential.

This global strategic report presents rates of MSC clinical trials, scientific publications, patents, funding events, and collaborations. It presents the pipeline for MSC-based therapeutics, identifies market opportunities and threats, and explores future directions and emerging applications. It reveals innovative MSC products, services, and technologies offered by 125 leading competitors. Finally, it presents detailed market size figures for the global MSC market, segmented by geography and business segment with future forecasts through 2031.

TABLE OF CONTENTS

1. REPORT OVERVIEW

• 1.1. Statement of the Report
• 1.2. Target Demographic
• 1.3. Sources for this Report
• 1.4. Purpose of the Report
  • 1.4.1. Survey Recent Advancements
  • 1.4.2. Provide a Summary of the Global MSC Market
  • 1.4.3. Access Opportunities for Commercialization
  • 1.4.4. Identify Major Market Players and Evaluate the Competive Environment
  • 1.4.5. Identify Existing and Emerging Trends
  • 1.4.6. Identify Critical Opportunities and Threats within the MSC Market
• 1.5. Executive Summary
• 1.6. Introduction

2. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW

• 2.1. Stabilization of hMSCs as a Technology
• 2.2. The Impact of MSCs on Regenerative Medicine
• 2.3. Timeline of MSC Nomenclature
• 2.4. Sources of MSCs
  • 2.4.1. Bone Marrow-Derived MSCs (BM-MSCs)
  • 2.4.2. Adipose-Derived MSCs (AD-MSCs)
  • 2.4.3. Umbilical Cord-Derived MSCs (UC-MSCs)
• 2.5. Cell Surface Markers in MSCs
• 2.6. In vitro Differentiation Potentials of MSCs
• 2.7. Soluble Factors Secreted by MSCs
• 2.8. Stemness Genes Present in MSCs
• 2.9. Types of MSCs and their Biomedical Applications
• 2.10. Genes that are Pivotal for MSC's Properties

3. MSC-BASED CLINICAL TRIAL LANDSCAPE

• 3.1. MSC-Based Clinical Studies by Geography
• 3.2. Sources of MSCs used in Current Clinical Trials
• 3.3. Share of Autologous & Allogeneic MSCs Clinical Trials
• 3.4. MSC-Based Clinical Trials by Disease Indication
• 3.5. MSC-Based Clinical Trials by Phase of Study
• 3.6. Select MSC-Based Clinical Trials
  • 3.6.1. MSC-Based Clinical Trials for Musculoskeletal Disorders
  • 3.6.2. MSC-Based Clinical Trials for Neurological Disorders
  • 3.6.3. Clinical Trials involving MSC-Drived Exosomes
  • 3.6.4. Primed MSCs in Clinical Trials
  • 3.6.5. Clinical Trials involving Scaffold-Based MSCs

4. MESENCHYMAL STEM CELLS (MSCS): PATENT LANDSCAPE

• 4.1. MSC Patent Publications by Jurisdiction
• 4.2. MSC Patent Applicants
• 4.3. MSC Patent Inventors
• 4.4. MSC Patent Owners
• 4.5. Legal Status of MSC Patent Applications
• 4.6. MSC-Derived Exosome Patents
  • 4.6.1. MSC-Derived Exosome Patents by Jurisdiction
  • 4.6.2. MSC-Derived Exosome Patent Applicants
  • 4.6.3. MSC-Derived Exosome Patent Inventors
  • 4.6.4. MSC-Derived Exosome Patent Owners
  • 4.6.5. Legal Status of MSC-Derived Exosome Patents
• 4.7. Patents for iPSC-Derived MSCs
  • 4.7.1. iPSC-Derived MSC Patents by Jurisdiction
  • 4.7.2. iPSC-Derived MSC Patent Owners
• 4.8. MSC Patents by Therapy Type

5. PUBLISHED SCIENTIFIC PAPERS ON MSCS

• 5.1. PubMed.gov Published Papers on MSCs in Cell Therapy
• 5.2. PubMed.gov Published Papers on MSC-Based Immunotherapies
• 5.3. PubMed.gov Published Papers on MSCs in Gene Therapy
• 5.4. PubMed.gov Published Papers on MSCs in Tissue Engineering
• 5.5. PubMed.gov Published Papers on MSCs in Aesthetics
• 5.6. Number of Published Papers on the Applications of MSCs in Major Diseases
• 5.7. Published Papers on Modified MSCs
• 5.8. Published Papers on MSC-Derived Exosomes

6. MSC MANUFACTURING PLATFORMS: AN OVERVIEW

• 6.1. Methods of Isolations of MSCs
• 6.2. Cell Expansion: Conventional Cultures to Bioreactors
  • 6.2.1. Monolayer Culture Systems
  • 6.2.2. Bioreactor-Based Cell Expansion
    • 6.2.2.1. Stirred Tank Bioreactor
    • 6.2.2.2. Rocking Bioreactor
    • 6.2.2.3. Hollow Fiber Bioreactors
    • 6.2.2.4. Fixed-Bed Bioreactor
  • 6.2.3. Bioreactors in Current Use
    • 6.2.3.1. Automated Platforms
    • 6.2.3.2. Miniaturized Bioreactors
    • 6.2.3.3. Verical-Wheel Bioreactors
  • 6.2.4. MSC Expansion Systems: A Snapshot
  • 6.2.5. Number of Cells per batch by Technologies
  • 6.2.6. Microcarriers used for Cell Expansion
• 6.3. Downstream Processing of MSCs
  • 6.3.1. Cell Detachment and Separation (Harvesting)
  • 6.3.2. Cell Washing and Concentration
  • 6.3.3. Safety and Potency Assays
  • 6.3.4. Surface Markers for Distinguishing MSCs from Fibroblasts
• 6.4. Autologous & Allogeneic MSC Manufacturing: A Comparison
  • 6.4.1. Cost of Manufacturing Allogeneic MSCs
  • 6.4.2. Cost of Manufacturing Autologous MSCs
  • 6.4.3. Cost of Donor Screening & Testing
  • 6.4.4. Cost of Release Testing
  • 6.4.5. Cost Breakdown in MSC Manufacturing
    • 6.4.5.1. Strategies for Cost Reduction
  • 6.4.6. Cost of Manufacture in Partial Automation
    • 6.4.6.1. CoG Breakdown in Partially Automated MSC Manufacturing
    • 6.4.6.2. CoG Breakdown in Fully Automated MSC Manufacturing
    • 6.4.6.3. Higher Throughput in Partially Automated Facilities
• 6.5. MSC Manufacturing Economics in Small Scale
  • 6.5.1. Small Scale Manufacturing Model
    • 6.5.1.1. Cost of Culture Media in Small Scale Manufacturing
• 6.6. Large Scale Manufacturing of MSCs
  • 6.6.1. The Four Bioprocessing Strategies for Large Scale Manufacturing of MSCs 129
  • 6.6.2. Commonly Used Sources of MSCs for Large Scale Expansion
  • 6.6.3. Commonly Used Culture Media for Large Scale Expansion of MSCs
  • 6.6.4. Expansion Ratios Achieved with Different Culture Media

7. CELL & GENE THERAPY CONTRACT MANUFACTURING

• 7.1. Staff Shortage
• 7.2. Need for Automation
• 7.3. Capacity Constraints
• 7.4. CDMO Platforms with Greater Potentials
  • 7.4.1. Type of CDMOs Used by Sponsors
• 7.5. CMOs/CDMOs
  • 7.5.1. Contract Manufacturing Organizations (CMOs)
    • 7.5.1.1. Major Services Offered by CMOs
  • 7.5.2. Contract Development and Manufacturing Organizations (CDMOs)
    • 7.5.2.1. Major CDMOs
    • 7.5.2.2. Major Services offered by CDMOs
• 7.6. Geographic Distribution of Manufacturing Facilities
• 7.7. Continued Rise of Outsourcing
  • 7.7.1. Specific Areas of Outsourcing
  • 7.7.2. Select Services for Outsourcing in 2023
  • 7.7.3. Expected Rate of Outsourcing Increase between 2023 and 2025
• 7.8. Major CDMOs in the U.S.
• 7.9. Major Cell & Gene Therapy CDMOs in Europe
• 7.10. U.K.'s Domination in European Contract Manufacturing
  • 7.10.1. GMP Manufacturing in U.K.
  • 7.10.2. Cleanroom Footprint in UK
  • 7.10.3. Cell Therapy Process Capabilities in U.K.
  • 7.10.4. Gene Therapy Process Capabilities in U.K.
  • 7.10.5. Future Capacity and Expansion in U.K.

8. BIOENGINEERING SOLUTIONS TO BOOST MSC'S FUNCTIONS

• 8.1. Small Molecule Priming of MSCs
• 8.2. Particle Engineering of MSCs
  • 8.2.1. Materials used in Microparticles (MPs) Fabrication
• 8.3. Genetic Engineering of MSCs
  • 8.3.1. Engineered MSCs as Living Drug Factories
• 8.4. Examples of Bioengineered MSCs to Produce Anticancer Therapeutics
• 8.5. Engineered MSCs for Neurological Conditions
• 8.6. Engineered MSCs for Cardiovascular Diseases
• 8.6. Engineered MSCs for Lung Injury
• 8.7. Engineered MSCs for Diabetes
• 8.8. Bioengineering Approaches to Improve MSC Administration

9. MAJOR DISEASES ADDRESSED BY MSCS

• 9.1. Studies Using MSCs for Autoimmune Diseases
• 9.2. Studies using MSCs for Cardiovascular Diseases
• 9.3. Studies using MSCs for Neurodegenerative Diseases
• 9.4. Studies using MSCs for Bone & Cartilage Diseases
• 9.5. Studies using MSCs in GvHD
• 9.6. Studies using MSCs in Crohn's Disease
• 9.7. Studies using MSCs in Type 1 Diabetes
• 9.8. Studies using MSCs in Systemic Lupus Erythematosus (SLE)
• 9.9. Studies using MSCs in Parkinson's Disease
• 9.10. Studies using MSCs in Alzheimer's Disease
• 9.11. Studies using MSCs in Kidney Failure
• 9.12. Studies using MSCs in Spinal Cord Injury
• 9.13. Studies using MSCs for Wound Healing

10. RECENT COLLABORATIONS IN MSC SECTOR, 2020-2024

• 10.1. Collaboration between BioSolution Designs & RoosterBio
• 10.2. Collaboration between CytoMed Therapeutics, Ltd. & Sengkang General Hospital
• 10.3. Collaboration between REPROCELL & Histocell
• 10.4. Collaboration between FUJIFILM Dyosynth & RoosterBio
• 10.5. RoosterBio's Collaboration with AGC Biologics
• 10.6. RoosterBio's Partnership with ShiftBio
• 10.7. RoosterBio's Partnership with Univercells Technologies
• 10.8. Collaboration between Cynata & Fujifilm
• 10.9. Collaboration between American CryoStem Corp. & BioTherapeutic Lab Corp.
• 10.10. RoosterBio's Collaboration with Sartorius
• 10.11. Collaboration between American CryoStem and CRADA
• 10.12. RoosterBio's Collaboration with Sartorius Korea Biotech
• 10.13. Collaboration between Catalent & BrainStorm
• 10.14. Collaboration between Cipla & Stempeutics
• 10.15. Aethlon's Collaboration with University of Pittsburgh
• 10.16. RoosterBio's Collaboration with Senti Biosciences

11. MSC-BASED PRODUCTS IN THE MARKET

• 11.1. Approved MSC Therapies
  • 11.1.1. Queencell
  • 11.1.2. Cellgram AMI
  • 11.1.3. Cupistem
  • 11.1.4. Cartistem
  • 11.1.5. NeuroNataR
  • 11.1.6. Holoclar
  • 11.1.7. Remestemcel-L
  • 11.1.8. Temcell HS
  • 11.1.9. Stempeucel
  • 11.1.10. Alifosel
  • 11.1.11. MesestroCell
  • 11.1.12. Stemirac
• 11.2. Marketed Biomaterial Carrier-Based MSCs & MSC Progenitors
  • 11.2.1. Osteocel
  • 11.2.2. AlloStem
  • 11.2.3. Grafix
  • 11.2.4. Cellentra VCBM
  • 11.2.5. Trinity ELITE
  • 11.2.6. Map3
  • 11.2.7. BIO4
  • 11.2.8. Trinity Evolution
  • 11.2.9. Carticel
  • 11.2.10. Chondron
  • 11.2.11. DeNovo NT
  • 11.2.12. Chondrocelect
  • 11.2.13. Ossron
  • 11.2.14. JACC
  • 11.2.15. MACI
  • 11.2.16. Ortho-ACI
  • 11.2.17. Ossgrow
  • 11.2.18. Cartigrow
• 11.3. Topical Cosmetic Products Containing MSCs/MSC-Derived Exosomes

12. MARKET ANALYSIS

• 12.1. Market Size for MSC Therapies
• 12.2. Global Demand for Mesenchymal Stem Cells (MSCs)
  • 12.2.1. Global Demand for MSCs in Academic and Preclinical Studies
  • 12.2.2. Global Demand for MSCs in Clinical Trials
  • 12.2.3. Global Demand for MSCs for Developing MSC Therapeutics
  • 12.2.4. Global Demand for MSCs to Develop Exosome Products
  • 12.2.5. Global Demand for MSCs in Emerging Industries
  • 12.2.6. Global Market for Mesenchymal Stem Cells (MSCs)
  • 12.2.7. Global MSC Market by Application

13. COMPANY PROFILES

• 13.1. Advancells
  • 13.1.1. MSC-Derived Exosome Therapy
• 13.2. Aegle Therapeutics
  • 13.2.1. Dystrophic Epidermolysis Bullosa
  • 13.2.2. Burns/Scarring
  • 13.2.3. Additional Indications
• 13.3. AGC Biologics
  • 13.3.1. Cell Therapy Manufacturing
  • 13.3.2. Services
• 13.4. AlloSource, Inc.
  • 13.4.1. Allografts with Tissue-Derived MSCs
  • 13.4.2. Products
    • 13.4.2.1. AlloConnex
    • 13.4.2.2. AlloFuse & AlloFuse Plus DBM
    • 13.4.2.3. AlloFlex Plus
    • 13.4.2.4. AlloFuse Cervical Grafts
    • 13.4.2.5. AlloFuse Fiber and Fiber Boats
    • 13.4.2.6. AlloFuse Select CM
• 13.5. Ambulero
  • 13.5.1. Supercharged MSCs
  • 13.5.2. Ambulero's Pipeline
• 13.6. American CryoStem Corporation
  • 13.6.1. Adult Stem Cell Storage Service
  • 13.6.2. Products Offered
    • 13.6.2.1. CELLECT
    • 13.6.2.2. ACSelerateMAX
    • 13.6.2.3. ATCELL
• 13.7. American Type Culture Collection (ATCC)
  • 13.7.1. Stem Cell Products
• 13.8. Amniotics
  • 13.8.1. Technology
  • 13.8.2. Product Pipeline
• 13.9. Andelyn Biosciences
  • 13.9.1. Andelyn's Solutions
• 13.10. Anemocyte S.r.l
  • 13.10.1. GMP Capacity
  • 13.10.2. Product Types
  • 13.10.3. Manufacturing Services
• 13.11. Anterogen, Co., Ltd.
  • 13.11.1. Products
    • 13.11.1.1. Cupistem Injection
    • 13.11.1.2. Queencell
• 13.12. Avid Bioservices, Inc.
  • 13.12.1. Services
• 13.13. Bacthera
  • 13.13.1. Services
• 13.14. Baylx, Inc.
  • 13.14.1. Technology
  • 13.14.2. Product Pipeline
    • 13.14.2.1. BX-U001 for Rheumatoid Arthritis
• 13.15. BioCardia
  • 13.15.1. Product Pipeline
• 13.16. BioCentriq
  • 13.16.1. Clinical Manufacturing Serevices
  • 13.16.2. Process Development Services
• 13.17. BioEden, Inc.
• 13.18. Bioinova s.r.o
  • 13.18.1. Products
  • 13.18.2. Services
    • 13.18.2.1. Storage & Transportation Solution
    • 13.18.2.2. Cryopreservation
    • 13.18.2.3. Autologous Therapy
    • 13.18.2.4. Allogeneic Therapy
• 13.19. BioRestorative Therapies
  • 13.19.1. BRTX-100
  • 13.19.2. ThermoStem
• 13.20. Bioscience Institute S.p.A
  • 13.20.1. Aesthetic Stem Cells
    • 13.20.1.1. LIPOSKILL for Skin Rejuvenation
    • 13.20.1.2. LIPOSKILL PLUS for Face Reshaping
    • 13.20.1.3. LIPOSKILL PLUS for Breast Augmentation
    • 13.20.1.4. LIPOSKILL PLUS for Buttock Enhancement
    • 13.20.1.5. LIPOSKILL PLUS for Reduction of Scars and Stretch Marks
    • 13.20.1.6. HAIRSKILL for Hair Loss Treatment
    • 13.20.1.7. GYNSKILL for Vulvo-Vaginal Rejuvenation
  • 13.20.2. Regenerativ Stem Cells
    • 13.20.2.1. ORTHOSKILL for Regenerative Orthopedics
    • 13.20.2.2. OVOSKILL for Early Menopause Treatment
    • 13.20.2.3. ANDROSKILL for Erectile Dysfunction Treatment
    • 13.20.2.4. Anti-Aging IV Therapy
    • 13.20.2.5. XEROSTOMIA Treatment
    • 13.20.2.6. Empty Nose Syndrome (ENS) Treatment
    • 13.20.2.7. Stem Cell Therapy for Body Performance
• 13.21. Blue Horizon International, LLC
  • 13.21.1. BHI's Stem Cell Division
• 13.22. Boehringer Ingelheim BioXellence
  • 13.22.1. Services
• 13.23. Bonus Biogroup, Ltd.
  • 13.23.1. BonoFill
  • 13.23.2. MesenCure
• 13.24. BrainStorm Cell Therapeutics, Inc.
  • 13.24.1. NurOwn Technology
  • 13.24.2. Manufacturing of NurOwn
  • 13.24.3. BrainStorm's Clinical Trials
• 13.25. Catalent
  • 13.25.1. Cell Therapy Process Development
  • 13.25.2. Cell Therapy CGMP Manufacturing
• 13.26. CCRM
• 13.27. Cell2Cure ApS
  • 13.27.1. Product
    • 13.27.1.1. Mode of Action
    • 13.27.1.2. Manufacture
• 13.28. Cell Care Therapeutics
  • 13.28.1. Platform
  • 13.28.2. CCT-101
• 13.29. Cellcolabs
  • 13.29.1. Ordering Cells
• 13.30. CELLeBRAIN
  • 13.30.1. Core Technology
  • 13.30.2. CELLeBRAIN's Product Pipeline
• 13.31. Cellipont Bioservices
  • 13.31.1. Cellipont's Capabilities
  • 13.33.2. Cellipont's Cell Expertise
• 13.34. Celprogen, Inc.
  • 13.34.1. Products
  • 13.34.2. Services
• 13.35. CellProthera
  • 13.35.1. ProtheraCytes
  • 13.35.2. Technology: StemXpand
• 13.36. CellResearch Corporation, Pte, Ltd.
  • 13.36.1. Umbilical Cord Lining Stem Cells
  • 13.36.2. CALECIM
• 13.37. Cell Surgical Network (CSN)
  • 13.37.1. Technology: The Time Machine 3.0 Auto
  • 13.37.2. Time Machine Process
• 13.38. Celltex Therapeutics Corporation
  • 13.38.1. Therapy Services
• 13.39. CellTherapies
  • 13.39.1. Services
  • 13.39.2. Contract Manufacturing
  • 13.39.3. Apheresis Management
  • 13.39.4. Clinical Trial Support
• 13.40. Cellular Biomedicine Group
• 13.41. Charless River Laboratories
  • 13.41.1. Cell Therapy Manufacturing Services
• 13.42. CHIESI Farmaceutici S.p.A
  • 13.42.1. Holoclar
• 13.43. Citius Pharmaceuticals, Inc.
  • 13.43.1. Stem Cell Platform
• 13.44. CorestemChemon, Inc.
  • 13.44.1. Neuronata-R inj.
• 13.45. Creative Bioarray
  • 13.45.1. MSC Services
  • 13.45.2. MSC Isolation and Expanson Services
  • 13.45.3. MSC Characterization Services
  • 13.45.4. MSC Differentiation Services
• 13.46. Creative Medical Technology Holdings, Inc.
  • 13.46.1. Rapid Autologous Therapies
  • 13.46.2. Creative Medical's Preclinical and Clinical Pipeline
• 13.47. Curia Global, Inc
  • 13.47.1. Services
• 13.48. Cynata Therapeutics, Ltd.
  • 13.48.1. Cymerus Platform
    • 13.48.1.1. CYP-001
    • 13.48.1.2. CYP-004
    • 13.48.1.3. Cymerus MSCs for ARDS
    • 13.48.1.4. CYP-006TK
• 13.49. Cytovance Biologics
  • 13.49.1. GMP Manufacturing
• 13.50. Defined Bioscience, Inc.
  • 13.50.1. Products
    • 13.50.1.1. Applications in Stem Cells
    • 13.50.1.2. Applications in Cultivated Meat
• 13.51. Direct Biologics
  • 13.51.1. ExoFlo
• 13.52. eQcell, Inc.
  • 13.52.1. Innovation
• 13.53. Excellos
• 13.54. Exosla Therapeutics
• 13.55. EXOSOMEplus
• 13.56. Exothera
  • 13.56.1. Exoscan Process Analysis Services
  • 13.56.2. Process Design & Development Services
  • 13.56.3. GMP Manufacturing Services
• 13.57. Fujifilm Diosynth Biotechnologies
  • 13.57.1. Cell & Gene Therapy Services
• 13.58. Future Cell Japan, Co., Ltd.
  • 13.58.1. Conditioned Media from UC-MSCs
• 13.59. Genezen
  • 13.59.1. Genezen's Capabilities
• 13.60. GenScript Biotech Corporation
  • 13.60.1. Cell Therapy Product Solutions
    • 13.60.1.1. CytoSinct Nanobeads
    • 13.60.1.2. CytoSinct Manual Separator System
    • 13.60.1.3. CytoSinct 1000
• 13.61. Hope Biosciences, LLC
  • 13.61.1. Adult Stem Cell Banking
  • 13.61.2. Newborn Stem Cell Banking
  • 13.61.3. Sponsored Clinical Trials
• 13.62. Implant Therapeutics, Inc.
  • 13.62.1. Services
• 13.63. INCELL Corporation LLC
  • 13.63.1. Product Line
  • 13.63.2. Cell & Tissue Products
  • 13.63.3. Tissue Collections & Kit Products
  • 13.63.4. Storage of Cell & Tissue Products
• 13.64. InGeneron GmbH
  • 13.64.1. Transpose RT Process
  • 13.64.2. Adipose-Derived Regenerative Cells (ADRCs)
• 13.65. Invitrx Therapeutics
  • 13.65.1. Reluma
• 13.66. Japan Tissue Engineering, Co., Ltd. (J-TEC)
  • 13.66.1. JACC
• 13.67. JCR Pharmaceuticals, Co., Ltd.
  • 13.67.1. TEMCELL HS Inj.
• 13.68. Jointechlabs
  • 13.68.1. Products
    • 13.68.1.1. MiniTC
    • 13.68.1.2. Mini-Stem
  • 13.68.2. Jointech's Products in Pipeline
    • 13.68.2.1. JTL-T-01 (Osteoarthritis Clinical Therapy)
    • 13.68.2.2. JTL-T-02 (Wounds Clinical Therapy)
• 13.69. Kangstem Biotech, Co., Ltd.
  • 13.69.1. Stem Cell Therapeutics
  • 13.69.2. Stem Cell Therapy
• 13.70. Kimera Labs
  • 13.70.1. Vive
  • 13.70.2. Luxir
• 13.71. LifeCell
  • 13.71.1. Large-Scale Manufacturing of MSCs
• 13.72. Longeveron
  • 13.72.1. Lomecel-B
  • 13.72.2. Clinical Pipeline
• 13.73. Longeveron
  • 13.73.1. Lomecel-B
    • 13.73.1.1. Manufacturing Method
  • 13.73.2. Focused Therapeutic Areas
    • 13.73.2.1. Hypoplastic Left Heart Syndrome (HLHS) Research Program
    • 13.73.2.2. Alzheimer's Disease (AD) Research Program
    • 13.73.2.3. Aging Frailty Research Program
• 13.74. Lonza Group, Ltd
  • 13.74.1. Sell& Gene Technologies Segment
  • 13.74.2. Bioscience Segment
  • 13.74.3. Personalized Medicines Segment
• 13.75. Lorem Cytori USA, Inc.
  • 13.75.1. Celution System
  • 13.75.2. Cytori Cell Therapy
• 13.76. MEDPOST
  • 13.76.1. Products
    • 13.76.1.1. CARTISTEM
    • 13.76.1.2. PNEUMOSTEM
    • 13.76.1.3. SMUP-IA-01
    • 13.76.1.4. SMUP-IV-01
• 13.77. Mesoblast, Ltd.
  • 13.77.1. Technology Platform
  • 13.77.2. Intellectual Property Estate
  • 13.77.3. Product Candidates
    • 13.77.3.1. Revascor
    • 13.77.3.2. MPC-06-ID
    • 13.77.3.3. Remestemcel-L
    • 13.77.3.4. MPC-300-IV
• 13.78. Millipore Sigma
  • 13.78.1. Cell Culture & Analysis Products
• 13.79. NecstGen
  • 13.79.1. Cell Therapy Development & Manufacturing
  • 13.79.2. Viral Vector Development & Manufacturing
  • 13.79.3. Cleanroom Rental
• 13.80. NextCell
  • 13.80.1. ProTrans
  • 13.80.2. Cellaviva
  • 13.80.3. NextCell's Products in Pipeline
• 13.81. NIPRO Corporation
  • 13.81.1. Stemirac
• 13.82. Novadip Biosciences
  • 13.82.1. The 3M3 Platform
  • 13.82.2. Products
• 13.82.2.1 3MAUTO
• 13.82.2.2 3MALLO
• 13.82.2.3 3MEXO
• 13.83. Novus Biologicals, LLC
• 13.84. NuVasive
  • 13.84.1. Osteocel Portfolio
    • 13.84.1.1. Osteocel Plus
    • 13.84.1.2. Osteocel Pro
• 13.85. OCT Therapies & Research Pvt., Ltd
• 13.86. OmniaBio, Inc.
  • 13.86.1. Services
    • 13.86.1.1. Process Development
    • 13.86.1.2. GMP Manufacturing
    • 13.86.1.3. Analytical Development
    • 13.86.1.4. Regulatory Guidance
• 13.87. Orthocell, Ltd.
  • 13.87.1. OrthoACI
• 13.88. Orthofix Medical, Inc.
  • 13.88.1. Trinity Elite
  • 13.88.2. Trinity Evolution
• 13.89. Ossium Health
  • 13.89.1. Platform
  • 13.89.2. Applications
    • 13.89.2.1. Hematologic Diseases
    • 13.89.2.2. Organ Transplant Rejection
    • 13.89.2.3. Musculoskeletal Defects
  • 13.89.3. Products
    • 13.89.3.1. OssiGraft Prime
    • 13.89.3.2. OssiGraft
    • 13.89.3.3. GMP Human Mesenchymal Stem Cells
    • 13.89.3.4. GMP Human Selected CD34+ Cells
    • 13.89.3.5. RUO Mesenchymal Stem Cells
    • 13.89.3.6. RUO Human Selected CD34+ Cells
• 13.90. Personal Cell Sciences Corporation
  • 13.90.1. Autokine CM
  • 13.90.2. Products
• 13.91. Personalized Stem Cells, Inc.
  • 13.91.1. Personalized Stem Cells for Knee Osteoarthritis
• 13.92. Pfizer CentreOne
  • 13.92.1. Manufacturing
• 13.93. Pluri Biotech, Ltd.
  • 13.93.1. PLX Products
• 13.94. Porton Advanced
  • 13.94.1. Cell Therapy Services
  • 13.94.2. LVV Services
  • 13.94.3. PLX-PAD
  • 13.94.4. PLX-R18
  • 13.94.5. PLX-Immune
• 13.95. Prometheus Life Technologies
  • 13.95.1. Organoids
• 13.96. PromoCell GmbH
  • 13.96.1. Products
• 13.97. PuREC, Co., Ltd.
  • 13.97.1. PuREC Solution for Hypophosphatasia
  • 13.97.2. PuREC Solution for Spinal Canal Stenosis
• 13.97. Regrow Biosciences
  • 13.97.1. Ossgrow
  • 13.97.2. Cartigrow
• 13.98. Reliance Life Sciences, Pvt., Ltd.
  • 13.98.1. Regenerative Medicine Products
• 13.99. Remedy Cell, Ltd.
  • 13.99.1. Proprietary Platform
  • 13.99.2. Drug Candidate: RC-0315
• 13.100. Rentschler Biopharma
  • 13.100.1. Services
• 13.101. REPROCELL USA, Inc.
  • 13.101.1. Services
  • 13.101.2. Products
• 13.102. Resilence
  • 13.102.1. Resilience's Capabilities
• 13.103. RESTEM, LLC
  • 13.103.1. Umbilical Cord Lining Stem Cells (ULSCs)
  • 13.103.2. Muscular Dystrophy - Clinical Trial
  • 13.103.3. Dermatomyositis & Polymyositis - Clinical Trial
  • 13.103.3. Heart Failure - Clinical Trial
• 13.104. RHEACELL GmbH & Co., KG
  • 13.104.1. Technology
  • 13.104.2. ABCB5+MSCs
• 13.105. Richter-HELM
  • 13.105.1. Services
• 13.106. RoosterBio, Inc.
  • 13.106.1. Technology
  • 13.106.2. Products
    • 13.106.2.1. Human Mesenchymal Stem Cells (hMSCs)
  • 13.106.3. Genetic Engineering Tools
    • 13.106.3.1. Genetic Engineering Media
  • 13.106.4. Cell Culture Media & Supplements
  • 13.106.5. Cell & Media Kits
  • 13.106.6. MSC-Derived Exosomes
  • 13.106.7. cGMP CliniControl Products
  • 13.106.8. Process Development Services
  • 13.106.9. hMSC Analytical Services
• 13.107. RTI Surgical
  • 13.107.1. Map3
• 13.108. RoslinCT
  • 13.108.1. Services
    • 13.108.1.1. Process Development
    • 13.108.1.2. GMP Manufacturing
    • 13.108.1.3. Quality Control
    • 13.108.1.4. Quality & Regulations
    • 13.108.1.5. Product Storage & Logistics
  • 13.108.2. RoslinCT-Lykan Bioscience Combine
• 13.109. Samsung Biologics
  • 13.109.1. Contract Manufacturing Capabilities
• 13.110. San Bio, Co., Ltd.
  • 13.110.1. SB623
• 13.111. Smith & Nephew, Inc.
  • 13.111.1. Grafix
• 13.112. StemBioSys, Inc.
  • 13.112.1. CELLvo Matrix Technology
  • 13.112.2. CELLVO hAD-MSCs
  • 13.112.3. CELLvo hBM-MSCs
  • 13.112.4. CELLvo hWJ-MSCs
  • 13.112.5. CELLvo Amniotic Membrane MSCs
• 13.113. STEMCELL Technologies, Inc.
  • 13.113.1. Products
    • 13.113.1.1. MSC & MSC Progenitor Cell Research Products
• 13.114. Stemedica Cell Technologies, Inc.
  • 13.114.1. BioSmart Technology
  • 13.114.2. Research & Development
• 13.115. Stemmatters
• 13.116. StemMedical
  • 13.116.1. Stemform Procedure
  • 13.116.2. Therapeutics Development
• 13.117. Stempeutics Research Pvt., Ltd.
  • 13.117.1. Stempeucel
• 13.118. StromaBio AB
  • 13.118.1. MSC Platform
• 13.119. TaiwanBio Therapeutics, Co., Ltd.
• 13.120. Takeda Pharmaceutical, Co., Ltd.
  • 13.120.1. Alofisel
• 13.121. Tempo Bioscience
  • 13.121.1. Tempo iMSCs
• 13.122. ThermoFisher Scientific
  • 13.122.1. CDMO Services for Cell Therapy
• 13.123. Vericel Corporation
  • 13.123.1. MACI
• 13.124. Wuxi App Tec
  • 13.124.1. CTDMO Services
• 13.125. Xintela AB
  • 13.125.1. Technology Platform
  • 13.125.2. Stem Cell Products
    • 13.125.2.1. XSTEM
    • 13.125.2.2. EQSTEM
    • 13.125.2.3. Cancer Therapy

INDEX OF FIGURES

• FIGURE 2.1: Mesenchymal Stem Cells and its Derivatives
• FIGURE 3.1: Increase in the Number of Registered MSC-Based Clinical Trials, 1995-2024
• FIGURE 3.2: MSC-Based Clinical Trials by Region
• FIGURE 3.3: MSC-Based Clinical Trials by Cell Source, 2024
• FIGURE 3.4: Share of Autologous & Allogeneic MSCs in Clinical Trials
• FIGURE 3.5: MSC-Based Clinical Trials by Indication
• FIGURE 3.6: Percent Share of MSC-Based Clinical Trials by Phase of Study
• FIGURE 4.1: MSC Patent Publications Over Time, 2000-Aug 2024
• FIGURE 4.2: MSC-Derived Exosome Patent Publications over Time
• FIGURE 4.3: iPSC-Derived MSCs Patent Publications over Time
• FIGURE 5.1: Published Papers in PubMed.gov on Mesenchymal Stem Cells (MSCs)
• FIGURE 5.2: PubMed.gov Published Papers on MSCs in Cell Therapy
• FIGURE 5.3: PubMed.gov Published Papers on MSC-Based Immunotherapies
• FIGURE 5.4: PubMed.gov Published Papers on MSCs in Gene Therapy
• FIGURE 5.5: PubMed.gov Published Papers on MSCs in Tissue Engineering
• FIGURE 5.6: PubMed.gov Published Papers on MSCs in Aesthetics
• FIGURE 5.7: PubMed Published Papers on Major Ten Diseases addressed by MSCs
• FIGURE 5.8: Number of Published Papers on Modified MSCs
• FIGURE 5.9: Number of Published Papers on MSC-Derived Exosomes
• FIGURE 6.1: Advantages and Disadvantages of Autologous & Allogeneic MSCs
• FIGURE 6.1: Monolayer Culture Systems
• FIGURE 6.2: Stirred Tank Bioreactor
• FIGURE 6.3: Rocking Bioreactor or Wave Bioreactor
• FIGURE 6.4: Hollow Fiber Bioreactor
• FIGURE 6.5: Fixed-Bed Reactor
• FIGURE 6.6: CompacT SelecT System from Sartorius
• FIGURE 6.7: DASbox Mini Bioreactor Systerm
• FIGURE 6.8: PBS-80 Vertical-Wheel Bioreactor
• FIGURE 6.9: Number of Cells per batch by Technologies
• FIGURE 6.10: Single-Use Harvestainer for Small Scale Application
• FIGURE 6.11: Single-Use Harvestainer for Large Scale Application
• FIGURE 6.12: Cost of Goods (CoG) in MSC Manufacturing
• FIGURE 6.13: Impact of Headcount on Overall CoG per Batch
• FIGURE 6.14: CoG Breakdown in Partially-Automated MSC Manufacturing
• FIGURE 6.15: CoG Breakdown in Fully Automated MSC Manufacturing
• FIGURE 6.16: Higher Throughput in Partially Automated Facilities
• FIGURE 6.17: Model of a Clean Room in a Small Scale Manufacturing Facility
• FIGURE 6.18: The Four Bioprocessing Strategies for Large Scale Manufacturing of MSCs
• FIGURE 6.19: Commonly Used Sources of MSCs for Large Scale Expansion
• FIGURE 6.20: Commonly Used Culture Media for Large Scale Expansion of MSCs
• FIGURE 7.1: CDMO Platforms with Greater Potentials
• FIGURE 7.2: Type of CDMOs Used by Sponsors
• FIGURE 7.3: Major Services Offered by CMOs
• FIGURE 7.4: Major Services used by Sponsors from CDMOs
• FIGURE 7.5: Geographic Distribution of Manufacturing Facilities, 2017-2027
• FIGURE 7.6: Percent Share of Outsourcing
• FIGURE 7.7: Select Services for Outsourcing in 2023
• FIGURE 7.8: Changing Priorities in Outsorcing Services between 2023 and 2025
• FIGURE 7.9: Cleanroom Footprint in UK, 2018-2023
• FIGURE 7.10: Cell Therapy Process Capabilities in U.K.
• FIGURE 7.11: Gene Therapy Process Capabilities in U.K.
• FIGURE 8.1: Bioengineering Solutions to Boost the Innate Functions of MSCs
• FIGURE 8.2: Bioengineering Approaches to MSC Administration
• FIGURE 9.1: Major Diseases Addresses by MSCs in Clinical Trials
• FIGURE 9.2: Percent Share of Autoimmune Diseases using MSCs in Clinical Trials
• FIGURE 9.3: Percent Share of MSCs by Source in Trials for Cardiovascular Diseases
• FIGURE 9.4: Percent Shares of Neurological Diseases in Clinical Trials using MSCs
• FIGURE 9.5: Percent Shares of MSC-Based Musculoskeletal Studies by Source
• FIGURE 12.1: Global Market for MSC-Based Therapeutics, 2023-2031
• FIGURE 12.2: Global Market for Mesenchymal Stem Cells (MSCs)
• FIGURE 12.3: Market Share of MSCs by Application
• FIGURE 13.1: CELLeBRAIN's Core Technology
• FIGURE 13.2: CALECIM
• FIGURE 13.3: Schematic Diagram of CytoSinct Nanobeads
• FIGURE 13.4: CytoSinct 1000
• FIGURE 13.5: Why-iPSC Derived MSCs (iMSCs)
• FIGURE 13.6: MiniTC
• FIGURE 13.7: Mini-Stem

INDEX OF TABLES

• TABLE 2.1: Timeline of MSC Nomenclature
• TABLE 2.2: Sources of MSCs
• TABLE 2.3: Advantages & Disadvantages of BM-MSCs
• TABLE 2.4: Advantages & Disadvantages of AD-MSCs
• TABLE 2.5: Advantages & Disadvantages of UC-MSCs
• TABLE 2.6: Positive & Negative Markers in MSCs from Different Sources
• TABLE 2.7: in vitro Differentiation Potentials of MSCs
• TABLE 2.8: Soluble Factors Secreted by MSCs
• TABLE 2.9: Some Typical "Stemness" Genes of MSCs
• TABLE 2.10: Types of MSCs and their Biomedical Applications
• TABLE 2.11: Genes that are Pivotal for MSC's Properties
• TABLE 3.1: MSC-Based Clinical Trials by Cell Source
• TABLE 3.2: Select MSC-Based Clinical Trials
• TABLE 3.3: Select MSC-Based Clinical Trials for Musculoskeletal Disorders
• TABLE 3.4: Select MSC-Based Clinical Trials for Neurological Disorders
• TABLE 3.5: Select Clinical Trials involving MSC-Drived Exosomes
• TABLE 3.6: Primed MSCs in Clinical Trials
• TABLE 3.7: Clinical Trials involving Scaffold-Based MSCs
• TABLE 4.1: MSC Patent Records by Jurisdiction, Aug-2024
• TABLE 4.2: MSC Patent Applicants, Aug-2024
• TABLE 4.3: MSC Patent Inventors
• TABLE 4.4: MSC Patent Owners
• TABLE 4.5: Legal Status of MSC Patent Applications
• TABLE 4.6: MSC-Derived Exosome Patents Jurisdiction
• TABLE 4.7: MSC-Derived Exosome Patent Applicants
• TABLE 4.8: MSC-Derived Exosome Patent Inventors
• TABLE 4.9: MSC-Derived Exosome Patent Owners
• TABLE 4.10: Legal Status of MSC-Derived Exosome Patents
• TABLE 4.11: iPSC-Derived MSC Patent Applications by Jurisdiction, August 2024
• TABLE 4.12: iPSC-Derived MSC Patent Owners
• TABLE 4.13: MSC Patents by Applications
• TABLE 5.1: PubMed Published Papers on Major Ten Diseases addressed by MSCs
• TABLE 5.2: Number of Published Papers on Modified MSCs
• TABLE 5.3: Number of Published Papers on MSC-Derived Exosomes
• TABLE 6.1: Methods of Isolations of MSCs
• TABLE 6.2: A Snapshot of Commercially Availabe Culture Systems
• TABLE 6.3: Microcarriers used for Cell Expansion
• TABLE 6.4: Basic Assays for MSCs
• TABLE 6.5: Cell Surface Markers on MSCs & Fibroblasts: A Comparison
• TABLE 6.6: Cost of Manufacturing Allogeneic MSCs
• TABLE 6.7: Cost of Manufacturing Autologous MSCs
• TABLE 6.8: Cost of Goods (CoG) in MSC Manufacturing
• TABLE 6.9: CoG Breakdown in Partially-Automated MSC Manufacturing
• TABLE 6.10: CoG Breakdown in Fully Automated MSC Manufacturing
• TABLE 6.11: Higher Throughput in Partially Automated Facilities
• TABLE 6.12: Key Processes and Cost Assumptions
• TABLE 6.13: Quality Control Panels and Cost Assumptions
• TABLE 6.14: Additional Supporting Labor Cost Assessments
• TABLE 6.15: Additional Supporting Facility and Cost Assumptions
• TABLE 6.16: Large Scale Expansions of MSCs by Method, Cell Source and Media
• TABLE 6.17: Expansion Ratios Achieved with Different Culture Media
• TABLE 7.1: Top Ten Companies in 2003 & 2027
• TABLE 7.2: GMP Capacities of U.S.-Based CDMOs
• TABLE 7.3: GMP Capacities of European CDMOs
• TABLE 7.4: MHRA-Licensed Manufacturing Facilities as of 2023
• TABLE 7.5: Cleanroom Footprint in UK, 2019-2023
• TABLE 8.1: Examples of Priming Strategies in Animal Models
• TABLE 8.2: Materials used in Microparticles (MPs) Fabrication
• TABLE 8.3: Genetic Engineering Method used in MSCs
• TABLE 8.4: Examples of Bioengineered MSCs as Living Drug Factories
• TABLE 8.5: Examples of Oncolology Indications being Studied using Engineered MSCs
• TABLE 8.6: Effects of Engineered MSCs in Neurological Indications
• TABLE 9.1: Select MSC-Based Clinical Trials for Autoimmune Diseases
• TABLE 9.3: Select MSC-Based Clinical Studies for Neurological Diseases
• TABLE 9.4: Select MSC-Based Studies for Musculoskeletal Disorders
• TABLE 9.5: Select Ongoing Studies using MSCs for GvHD
• TABLE 9.6: Studies using MSCs in Crohn's Diseases
• TABLE 9.7: Select Studies using MSCs in Type 1 Diabetes
• TABLE 9.8: Select Studies using MSCs in Systemic Lupus Erythematosus (SLE)
• TABLE 9.9: Select Studies using MSCs in Parkinson's Disease
• TABLE 9.10: Select Ongoing Studies using MSCs in Alzheimer's Disease
• TABLE 9.11: Select Ongoing Studies using MSCs in Kidney Failure
• TABLE 9.12: Select Studies using MSCs in Spinal Cord Injury
• TABLE 9.13: Select Studies using MSCs for Wound Healing
• TABLE 11.1: Currently Available MSC Therapies
• TABLE 11.2: Queencell - Product Information
• TABLE 11.3: Cellgram AMI - Product Information
• TABLE 11.4: Cupistem - Product Information
• TABLE 11.5: Cartistem - Product Information
• TABLE 11.6: NeuroNataR - Product Information
• TABLE 11.7: Holoclar - Product Information
• TABLE 11.8: Remestemcel-L - Product Information
• TABLE 11.9: Temcell HS - Product Information
• TABLE 11.10: Stempeucel - Product Information
• TABLE 11.11: Alifosel - Product Information
• TABLE 11.12: MesestroCell - Product Information
• TABLE 11.13: Stemirac - Product Information
• TABLE 11.14: Previous/Currently Marketed Biomaterial-Based MSCs & MSC Progenitors
• TABLE 11.15: Osteocel - Product Information
• TABLE 11.16: AlloStem - Product Information
• TABLE 11.17: Grafix - Product Information
• TABLE 11.18: Cellentra VCBM - Product Information
• TABLE 11.19: Trinity ELITE - Product Information
• TABLE 11.20: Map3 - Product Information
• TABLE 11.21: Bio4 - Product Information
• TABLE 11.22: Trinity Evolution - Product Information
• TABLE 11.23: Carticel - Product Information
• TABLE 11.24: Chondron - Product Information
• TABLE 11.25: DeNovo NT - Product Information
• TABLE 11.26: Chondrocelect - Product Information
• TABLE 11.27: Ossron - Product Information
• TABLE 11.28: JACC - Product Information
• TABLE 11.29: MACI - Product Information
• TABLE 11.30: Ortho-ACI - Product Information
• TABLE 11.31: Ossgrow - Product Information
• TABLE 11.32: Cartigrow - Product Information
• TABLE 11.33: Commercially Available Skincare Cosmetics with MSC-Derived Exosomes
• TABLE 12.1: Global Market for MSC-Based Therapeutics, 2023-2031
• TABLE 12.2: Global Market for Mesenchymal Stem Cells (MSCs)
• TABLE 13.1: Aegle's Product Pipeline
• TABLE 13.2: Ambulero's Product Pipeline
• TABLE 13.3: Amniotgics' Product Pipeline
• TABLE 13.4: Baylx's Product Pipeline
• TABLE 13.5: BioCardia's Product Pipeline
• TABLE 13.6: Bonus Biogroup's Product Pipeline
• TABLE 13.7: BrainStorm's Clinical Trials
• TABLE 13.8: CELLeBRAIN's Product Pipeline
• TABLE 13.9: CellProthera's Preclinical and Clinical Pipeline
• TABLE 13.10: Celltex's Clinical Trials
• TABLE 13.11: Corestem's Product Pipeline
• TABLE 13.12: Creative Medical's Preclinical and Clinical Pipeline
• TABLE 13.13: Regulatory Proteins found in ExoFlo
• TABLE 13.14: Hopes Clinical Trial Pipeline using HB-adMSC
• TABLE 13.15: Kangstem's Sponsor Initiated Clinical Trials
• TABLE 13.16: Longeveron's Clinical Pipeline
• TABLE 13.17: NextCell's Products in Pipeline
• TABLE 13.18: Novadip's Product Pipeline
• TABLE 13.19: RHEACELL's Products in Pipeline
• TABLE 13.20: San Bio's Product Pipeline
• TABLE 13.21: Stemedica's Product Pipeline
• TABLE 13.22: Stempeutics' Product Development Status
• TABLE 13.23: Xintela's Product Pipeline

관련자료